INTRODUCTION
============

The phosphatidylinositol 3-kinase (PI3K)/AKT signaling pathway plays an important role in cellular processes, such as proliferation, differentiation, survival, and migration ([@b1-cln_67p1285]),([@b2-cln_67p1285]). Alterations in the components of this signaling pathway, including gain-of-function mutations in the p110 catalytic subunit of PI3K, have been identified in a wide spectrum of human cancers ([@b3-cln_67p1285]),([@b4-cln_67p1285]). Class I PI3Ks are heterodimers composed of catalytic (p110) and regulatory (p85) subunits involved in regulating cell division and in tumorigenesis ([@b5-cln_67p1285]),([@b6-cln_67p1285]).

The *PIK3CA* gene comprises 20 exons encoding the p110α catalytic subunit. This gene is mutated in a wide range of tumors, including glioblastomas, gastric cancers, lung cancers, ovarian cancers, hepatocellular carcinomas, endometrial carcinomas, brain cancers, and breast cancers ([@b3-cln_67p1285]). The majority of *PIK3CA* mutations cluster in hotspot regions in exon 9 (the helical domain) and exon 20 (the kinase domain). The most common missense mutations change amino acid residues E542 and E545 to lysine in the helical domain and change H1047 to arginine in the kinase domain. Functional studies suggest that these particular *PIK3CA* mutations lead to increased PI3K activity ([@b6-cln_67p1285]),([@b7-cln_67p1285]).

The frequency of *PIK3CA* mutations in breast cancer ranges from 16.4 to 45% ([@b3-cln_67p1285]),. However, the association between *PIK3CA* mutations and specific clinicopathological features of breast cancer is still a matter of debate. Furthermore, the relationship between the presence of *PIK3CA* mutations in breast cancer patients and overall survival (OS) and disease-free survival (DFS) is controversial. Some studies have found that breast cancer patients with *PIK3CA* gene mutations have improved OS and DFS rates compared with breast cancer patients lacking such mutations ([@b9-cln_67p1285]),. Conversely, other studies have found that the presence of *PIK3CA* mutations is correlated with poor outcome ([@b14-cln_67p1285])([@b15-cln_67p1285])([@b16-cln_67p1285]).

In the present study, we identified mutations in exons 9 and 20 of the *PIK3CA* gene in primary breast tumors from Brazilian breast cancer patients, and we analyzed the relationship between mutational status and patient clinicopathological features and outcomes.

MATERIALS AND METHODS
=====================

Tumor samples and genomic DNA extraction
----------------------------------------

Samples from 86 primary breast tumors were obtained from breast cancer patients diagnosed at the Hospital do Cancer A. C. Camargo, São Paulo, Brazil, from February 1993 to March 1998. The median follow-up time was 63.3 months (range, 25 to 78 months). None of the patients had received any medical treatment related to their breast cancer before the biopsy/mastectomy procedure. After surgical excision, biopsy specimens were immediately frozen and stored in liquid nitrogen until DNA extraction. Histopathological review of the tumor slides was performed to confirm the diagnosis. All tumors were classified according to the World Health Organization Histological Typing of Breast Tumors classification, and the clinical stage of each patient was determined according to the 5^th^ Edition of the UICC TNM classification of malignant tumors. The tumors were all infiltrating ductal carcinomas. The median age of the patients at the time of diagnosis was 55 years (range, 26 to 85 years). The patient and tumor characteristics are shown in [Table 1](#t1-cln_67p1285){ref-type="table"}. Tissue specimens were ground to a powder under liquid nitrogen using a Frozen Tissue Pulverizer (Termovac Industries, Copiague, N.Y.), and high-molecular-weight DNA was extracted as previously described ([@b17-cln_67p1285]). This study was approved by the Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo Ethics Committee. All subjects were given information about the study and provided written informed consent.

Mutation analysis by polymerase chain reaction-single stranded conformation polymorphism (PCR-SSCP) and direct DNA sequencing
-----------------------------------------------------------------------------------------------------------------------------

Two sets of primers were used to amplify exon 9 (forward: 5′-CCAGAGGGGAAAAATATGACA-3′; reverse: 5′-CATTTTAGCACTTACCTGTGAC-3′) and exon 20 (forward: 5′-CATTTGCTCCAAACTGACCA-3′; reverse: 5′-TGAGCTTTCATTTTCTCAGTTATCTTTTC-3′) of the *PIK3CA* gene. The PCR products were separated using the GeneGel^TM^ Excel 12.5/24 Kit (GE Healthcare, Sweden) according to the manufacturer\'s instructions. Gels were stained using the DNA Silver Staining Kit (GE Healthcare) according to the manufacturer\'s instructions. Samples exhibiting differences in gel band mobility were cloned (TOPO-TA Cloning® Kit, Invitrogen) and then sequenced using a MegaBACE 1000 automatic sequencer (Amersham Biosciences) and the ET Dye Terminator Kit (Amersham Biosciences). All sequences were analyzed using Mutation Surveyor software v3.2 (SoftGenetics).

Statistical analysis
--------------------

Fisher\'s exact test and Spearman\'s rho correlation were used to assess the association and the direction of the association, respectively, among categorical variables. OS and DFS rates were calculated based on the Kaplan-Meier method, and the curves were compared using the log-rank test. OS and DFS rates were determined from the day of the diagnosis to the date of death or to the date on which recurrence was detected, respectively.

Statistical analyses were performed using IBM SPSS Statistics 19.0, 2010 (SPSS Chicago, IL). Differences were considered significant when the *p-*value was less than 0.05.

RESULTS
=======

We investigated mutations in exon 9 and exon 20 of the *PIK3CA* gene in 86 primary breast tumors by performing SSCP analysis and DNA sequencing. Of the 86 tumors, 23 (27%) exhibited *PIK3CA* mutations: 13% in exon 9 and 14% in exon 20. [Table 2](#t2-cln_67p1285){ref-type="table"} lists the *PIK3CA* variants identified by DNA sequencing. We characterized seven non-synonymous variants, two of which were new (I1022V, L1028S); three synonymous variants, two of which were new (S541S, L1028L); one new stop codon-gain variant (R992X); and one previously known stop codon-loss (X1069W) variant. [Figure 1](#f1-cln_67p1285){ref-type="fig"} shows representative electropherograms of the *PIK3CA* variants characterized in the primary breast tumors. New variants were considered mutations, as they were not present in the paired normal tissue of the same patients (data not shown). The frequency of the hotspot mutation E545K was 8.1%, corresponding to 63.6% of the helical (exon 9) mutations. The other common helical (exon 9) mutation, E542K, was observed in only one case. The kinase (exon 20) hotspot mutation H1047R was observed at a frequency of 14%, representing 91.7% of the *PIK3CA* exon 20 mutations.

Next, we investigated whether *PIK3CA* mutations were associated with breast cancer development and progression. The demographic and clinicopathological characteristics of patients with tumors containing *PIK3CA* mutations were compared with those of patients with tumors lacking *PIK3CA* mutations. There were no statistically significant differences between the clinicopathological features or steroid hormone receptor status in patients with or without *PIK3CA* mutations ([Table 3](#t3-cln_67p1285){ref-type="table"}).

Using a data set of *TP53* mutations published previously by our group ([@b17-cln_67p1285]), we evaluated whether any of the 73 patients had both *PIK3CA* and *TP53* mutations. None of the tumors with exon 9 *PIK3CA* mutations (PIK9^mut^) also contained *TP53* mutations. In contrast, we observed a correlation between the presence of exon 20 *PIK3CA* mutations (PIK20^mut^) and *TP53* mutations (Fisher\'s test *p-*value = 0.05, Spearman\'s correlation = 0.03, r = 0.253; [Table 3](#t3-cln_67p1285){ref-type="table"}.

We also tested whether *PIK3CA* mutations were associated with patient OS or DFS. A comparison of patients who had tumors with or without *PIK3CA* mutations revealed no significant differences in cancer-specific survival. On the other hand, when patients were grouped according to the presence of PIK3CA helical domain (exon 9) or kinase domain (exon 20) mutations, the presence of exon 20 mutations was associated with poorer OS (*p* = 0.026) and DFS (*p* = 0.079) ([Table 4](#t4-cln_67p1285){ref-type="table"} and [Figure 2](#f2-cln_67p1285){ref-type="fig"}). We further analyzed the relationship between survival and exon 20 mutations by conducting Kaplan-Meier analyses. We found that patients with tumors harboring exon 20 mutations had a significantly shorter mean OS and DFS compared with patients lacking exon 20 mutations (median OS: 24.1 months and not reached, respectively, *p* = 0.007; median DFS: 15.9 months and not reached, respectively, *p* = 0.025) ([Table 4](#t4-cln_67p1285){ref-type="table"} and [Figure 2](#f2-cln_67p1285){ref-type="fig"}).

DISCUSSION
==========

No previous study has investigated the frequency and spectrum of *PIK3CA* mutations in primary tumors from Brazilian breast cancer patients. In this study, we identified *PIK3CA* mutations in primary breast tumors from a group of Brazilian breast cancer patients and correlated these mutations with patient clinicopathological features and outcomes. The observed frequency of *PIK3CA* mutations was 27%, which is in accordance with similar studies that have examined the frequency of exon 9 and 20 mutations (frequency range, 16.4 to 45%) ([@b3-cln_67p1285]),. This result indicates that *PIK3CA* mutations are quite common genetic events in tumors in Brazilian breast cancer patients. The frequency of the most common missense activating mutations (E542K, E545K, and H1047R) in the primary breast tumors was 82.6%, the same rate previously reported in the literature ([@b11-cln_67p1285]). We also identified three new *PIK3CA* variants, two missense variants, and one nonsense variant. These variants were considered mutations, as they were not present in the paired normal tissue of the same patients (data not shown).

In our analysis of the relationship between *PIK3CA* mutations and patient clinicopathological characteristics, we found no significant correlations between *PIK3CA* mutations and patient age, clinical stage, tumor size, or lymph node metastasis. Some previous studies showed significant associations between *PIK3CA* mutations and steroid hormone (estrogen and/or progesterone) receptor status in breast cancer patients ([@b13-cln_67p1285]),([@b14-cln_67p1285]),([@b18-cln_67p1285]),([@b19-cln_67p1285]), while others failed to find such associations ([@b12-cln_67p1285]),([@b15-cln_67p1285]). Although the association between *PIK3CA* mutations and steroid hormone receptor status did not reach statistical significance, we observed a higher frequency of *PIK3CA* mutations in estrogen receptor-positive tumors compared with receptor--negative tumors, mainly in exon 9.

The association between *PIK3CA* mutations and breast cancer patient survival remains controversial. In the present work, we found that kinase domain (exon 20) mutations were strongly associated with poorer OS and DFS. Various studies have reported that the presence of *PIK3CA* mutations is associated with good prognosis ([@b11-cln_67p1285]),([@b13-cln_67p1285]), is associated with poor prognosis ([@b14-cln_67p1285]),([@b16-cln_67p1285]), or has no survival effect ([@b18-cln_67p1285]),([@b20-cln_67p1285]) in breast cancer patients. Kalinsky et al. ([@b13-cln_67p1285]) found a direct association between the presence of mutations in the C2, helical, or kinase functional domains and better DFS or OS. They also found that the H1047R mutation was strongly associated with the absence of lymph node metastasis ([@b13-cln_67p1285]). Similarly, Maruyama et al. ([@b11-cln_67p1285]) described a positive correlation between the presence of mutations in any domain of the *PIK3CA* gene and better relapse-free survival. Taken together, these studies suggest a protective role for these mutations. On the other hand, similar to our study, two other studies reported that exon 20 mutations were associated with poorer OS ([@b14-cln_67p1285]),([@b16-cln_67p1285]). It is difficult to compare these studies because of the studies\' population heterogeneity and because there may have been differences in the therapeutic strategies not mentioned in the publications.

Mutations in *TP53* and *PIK3CA* are frequent in breast cancer ([@b21-cln_67p1285]). In the present study, we found a positive correlation between the presence of *PIK3CA* exon 20 and *TP53* mutations, with four samples exhibiting mutations in both genes. This result suggests that the presence of these mutations is not mutually exclusive, as was proposed by Boyault et al. ([@b19-cln_67p1285]). We previously reported that patients with tumors harboring *TP53* mutations affecting amino acids involved directly in DNA or zinc binding had a poor prognosis ([@b17-cln_67p1285]). Interestingly, in this study, we found that the presence of *PIK3CA* exon 20 mutations could be used to stratify patients into distinct prognostic groups, regardless of whether a *TP53* mutation was present.

In summary, this is the first study to report that *PIK3CA* mutations are common in tumors in Brazilian breast cancer patients. We found that *PIK3CA* exon 20 mutations were significantly associated with TP53 mutations, indicating that PIK3CA mutations and TP53 mutations are not mutually exclusive. Our finding that *PIK3CA* exon 20 mutations were associated with more aggressive breast cancer and poor outcomes, regardless of the treatment regimen, has important clinical implications.
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![Representative eletropherograms of the *PIK3CA* mutations characterized in the breast cancer biopsy samples in this study. (A) Known mutations and (B) new mutations.](cln-67-11-1285-g001){#f1-cln_67p1285}

![Kaplan-Meier curves showing long-term survival in primary breast cancer patients, stratified according to *PIK3CA* mutation status. (A) Overall survival and (B) disease-free survival curves were calculated for the stratified patient groups. 'No\' indicates patients with tumors with no *PIK3CA* mutations; 'PIK9\' indicates patients with tumors with *PIK3CA* mutations in exon 9; and 'PIK20\' indicates patients with tumors with *PIK3CA* mutations in exon 20. (C) Overall survival and (D) disease-free survival curves were calculated for the stratified patient groups. 'No\' indicates patients with tumors with no *PIK3CA* mutations in exon 20, and 'Yes\' indicates patients with tumors with *PIK3CA* mutations in exon 20. *p*-values were calculated using the log-rank test.](cln-67-11-1285-g002){#f2-cln_67p1285}

###### 

Patient and tumor characteristics (n = 86).

  Variable      Characteristic   n (%)
  ------------- ---------------- -----------
  Age, y        ≤55              45 (52.3)
                \>55             41 (47.7)
  Stage, TNM    Early            37 (43.0)
                Late             49 (57.0)
  Tumor size,   \<4.0            44 (51.2)
  cm            ≥4.0             42 (48.8)
  Lymph node    Negative         22 (25.6)
  Metastasis    Positive         64 (74.4)
  Hormonal      Pre-menopause    30 (34.9)
  status        Post-menopause   56 (65.1)
  ER            Negative         27 (31.4)
                Positive         53 (61.6)
                Missing          06 (7.0)
  PR            Negative         43 (50.0)
                Positive         37 (43.0)
                Missing          06 (7.0)
  HER2          Negative         71 (82.6)
                Positive         08 (9.3)
                Missing          07 (8.1)
  TP53*^Mut^*   No               63 (73.3)
                Yes              10 (11.6)
                Missing          13 (15.1)

TNM: tumor, nodes, and metastases; ER: estrogen receptor;

PR: progesterone receptor; HER2: human epidermal growth factor receptor 2.

###### 

Observed variations in *PIK3CA* mutations in exons 9 and 20 in breast tumors (n = 86).

  Nucleotide   Variation ID   Residue   Variation type
  ------------ -------------- --------- -----------------------
  70282G\>A    COSM763        E545K     Non-synonymous coding
  70223A\>G    COSM41783      E525G     Non-synonymous coding
  70273G\>A    COSM760        E542K     Non-synonymous coding
  70272T\>G    \-             S541S     Synonymous coding
  86110C\>T    \-             R992X     Stop codon gained
  86171A\>G    COSM27130      E1012G    Non-synonymous coding
  86200A\>G    \-             I1022V    Non-synonymous coding
  86211C\>T    rs17849079     T1025T    Synonymous coding
  86218T\>C    \-             L1028L    Synonymous coding
  86219T\>C    \-             L1028S    Non-synonymous coding
  86276A\>G    COSM775        H1047R    Non-synonymous coding
  86343A\>G    COSM17449      X1069W    Stop codon lost

###### 

Association between the presence of *PIK3CA* mutations and patient and tumor characteristics.

  Variable          Category              *PIK^mut^*   *p-*value[\*](#tfn3-cln_67p1285){ref-type="table-fn"})   *PIK9^mut^*   *p-*value[\*](#tfn3-cln_67p1285){ref-type="table-fn"})   *PIK20^mut^*   *p-*value[\*](#tfn3-cln_67p1285){ref-type="table-fn"})             
  ----------------- ---------------- ---- ------------ -------------------------------------------------------- ------------- -------------------------------------------------------- -------------- -------------------------------------------------------- ---- ---- ------
  Age, y            \<55             45   34           11                                                       0.63          40                                                       5              0.75                                                     39   6    1.00
                    ≥55              41   29           12                                                                     35                                                       6                                                                       35   6    
  Stage,            Early            37   28           9                                                        0.81          31                                                       6              0.52                                                     34   3    0.22
  TNM               Late             49   35           14                                                                     44                                                       5                                                                       40   9    
  Tumor size,       \<4.0            39   31           8                                                        0.33          34                                                       5              1.00                                                     36   3    0.21
  Cm                ≥4.0             47   32           15                                                                     41                                                       6                                                                       38   9    
  Lymph node        Negative         22   17           5                                                        0.78          18                                                       4              0.46                                                     21   1    0.28
  metastasis        Positive         64   46           18                                                                     57                                                       7                                                                       53   11   
  Hormonal status   Pre-menopause    30   25           5                                                        0.13          28                                                       2              0.31                                                     28   2    0.53
                    Post-menopause   56   38           18                                                                     47                                                       9                                                                       47   9    
  ER                Negative         27   22           5                                                        0.19          26                                                       1              0.09                                                     23   4    1.00
                    Positive         53   35           18                                                                     43                                                       10                                                                      45   8    
  PR                Negative         43   33           10                                                       0.45          39                                                       4              0.33                                                     37   6    1.00
                    Positive         37   25           12                                                                     30                                                       7                                                                       32   5    
  HER2              Negative         71   54           17                                                       0.20          63                                                       8              1.00                                                     62   9    0.10
                    Positive         8    4            4                                                                      7                                                        1                                                                       5    3    
  TP53*^mut^*       No               63   44           19                                                       0.71          52                                                       11             0.34                                                     55   8    0.05
                    Yes              10   6            4                                                                      10                                                       0                                                                       6    4    

\*Fisher\'s exact test.

###### 

Association between *PIK3CA* mutations and patient survival.

  Category     *n*     Survivalrate   Overall survival   Disease-free survival                  
  ------------ ------- -------------- ------------------ ----------------------- ------- ------ -------
  PIK^mut^     No      50             70.0               NR                      0.163   NR     0.257
               Yes     22             54.5               NR                              NR     
  PIK^mut^     No      50             70.0               NR                      0.026   NR     0.079
               PIK9    10             70.0               NR                              NR     
               PIK20   12             41.7               24.1                            15.9   
  PIK9^mut^    No      62             64.5               NR                      0.548   NR     0.531
               Yes     10             70.0               NR                              NR     
  PIK20^mut^   No      60             70.0               NR                      0.007   NR     0.025
               Yes     12             41.7               24.1                            15.9   

Median survival reported in months; NR: not reached.
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